Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
- Conditions
- Diabetic NeuropathiesDiabetes MellitusChronic Pain
- Interventions
- Registration Number
- NCT01939366
- Lead Sponsor
- Tris Pharma, Inc.
- Brief Summary
The purpose of this trial is to evaluate if cebranopadol is safe and can decrease pain in patients when compared to placebo (a tablet that does not contain active product) and when compared to a marketed product containing pregabalin (Lyrica®). Furthermore, this trial will be undertaken to find out if the patient's general health and well-being improves under trial treatment.
The concentrations of cebranopadol in the blood will be investigated to get a better understanding of how it is absorbed from the gut, distributed and broken down in the body, and eliminated from the body.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 699
- written signed informed consent
- type 1 or type 2 diabetes mellitus
- clinical diagnosis of painful Diabetic Polyneuropathic Neuropathy (DPN) with symptoms and signs for at least 3 months
- must require medication (e.g., non-opioids or opioids up to an equivalent dose of 160 mg oral morphine/day) for the treatment of pain due to DPN for at least 1 month prior to Visit 1 and must be dissatisfied with the current treatment (in terms of efficacy and/or tolerability). Medication for the treatment of pain due to DPN should be required on at least 4 of 7 consecutive days.
- blood glucose to be controlled by a diet, oral anti-hyperglycemic medication, and/or insulin for at least 3 months prior. Glycosylated hemoglobin (HbA1C) should not be greater than 11%
- baseline pain intensity score greater or equal to 5 on the 11-point Numerical Rating Scale (NRS) without intake of any analgesic at allocation. For each of the last 3 days prior to allocation of treatment, a 24 hour NRS score greater or equal to 4 is required
- women of childbearing potential must have a negative urine pregnancy test at enrollment
- using medically acceptable and highly effective methods of birth control (and willing to use them during the trial).
- presence of other pain that could confound the painful Diabetic Polyneuropathy (DPN) assessments, e.g. pain due to nerve entrapment (tarsal tunnel syndrome, osteoarthritis of the knee etc), peripheral vascular disease, radiculopathy, plantar fasciitis, tendonitis, mononeuritis multiplex, postherpetic neuralgia, complex regional pain syndrome, or fibromyalgia.
- neuropathy due to etiologies other than diabetes, e.g. autoimmune disorders, inflammatory neuropathies (e.g. chronic inflammatory demyelinating polyneuropathy), thyroid disease or endocrine disorders (other than diabetes), heavy metal or toxic neuropathy, nutritional deficiency, metabolic disorders, vasculitis, infections, injury, or paraneoplastic syndromes.
- severe or extensive diabetic ulcers or amputations due to diabetes
- Charcot's joints due to diabetes.
- any clinically significant disease or laboratory findings, e.g., significant unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, metabolic, neurological, or psychiatric disorders.
- inability to comply with the protocol and with the intake of trial medication that, in the investigator's opinion, might indicate that the participant is unsuitable for the trial.
- conditions that require treatment with medication that is not allowed to be taken during the trial
- previous or current alcohol or drug abuse or opioid dependency.
- severe functional hepatic impairment corresponding to Child-Pugh classification C.
- history of acute hepatitis
- impaired renal function, a creatinine clearance less than 60 mL/min at the enrollment (Cockcroft-Gault calculated).
- history of any major gastrointestinal procedures (e.g., gastric bypass) or gastrointestinal conditions (e.g. acute diarrhea, blind loop syndrome, gastric dumping syndrome, Whipple's disease) that might affect the absorption or metabolism of cebranopadol or pregabalin.
- risk factors for or history of torsade de pointes and/or marked prolongation of the QT interval (e.g. heart failure, hypokalemia, or bradycardia).
- history of seizure disorder and/or epilepsy or any condition associated with a significant risk for seizure disorder or epilepsy at the discretion of the investigator.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cebranopadol 600 µg Cebranopadol 600 µg - Matching Placebo Matching Placebo - Cebranopadol 300 µg Cebranopadol 300 µg - Cebranopadol 100 µg Cebranopadol 100 µg - Pregabalin Pregabalin -
- Primary Outcome Measures
Name Time Method Change in Average Pain Intensity. Baseline; to End of Week 6 of the Maintenance Phase Participants will be asked to record their pain intensity in the evening. Participants are asked to rate how much pain they had on average in the past 24 hours. The participant scores their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". Baseline average pain scores are calculated from the averages of all scores recorded during the 3 days prior to randomization. The average pain at week 6 will be the average pain scores calculated from all pain scores measured during week 6.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (82)
US002
🇺🇸Mesa, Arizona, United States
US001
🇺🇸Garden Grove, California, United States
US019
🇺🇸Laguna Hills, California, United States
US014
🇺🇸National City, California, United States
US007
🇺🇸Orange, California, United States
US011
🇺🇸Hialeah, Florida, United States
US012
🇺🇸Miami, Florida, United States
US009
🇺🇸Orlando, Florida, United States
US004
🇺🇸Blackfoot, Idaho, United States
US006
🇺🇸Elgin, Illinois, United States
Scroll for more (72 remaining)US002🇺🇸Mesa, Arizona, United States